PET FDG Assessment of Change in Atherosclerotic Plaques After Chemotherapy
- Conditions
- Atherosclerosis
- Registration Number
- NCT00742352
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Brief Summary
The purpose of this study is to determine whether chemotherapy induces regression in atherosclerotic plaques in oncologic patients already undergoing PET FDG as part of their routine assessment.We will use PET FDG to assess whether the inflammation in atherosclerotic plaques is affected by chemotherapy and anti angiogenic therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
- Women over the age of 65 diagnosed with metastatic breast cancer
- Men over the age of 65 diagnosed with lung cancer
Exclusion Criteria
- Patients under the age of 65
- Patients diagnosed with chronic inflammatory disease or chronic infection
- Patients taking steroids and NSAIDS on a regular basis
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Tel-Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel